SavedAdd your journal

Journals / Experimed / 2013 / Cilt: 3 - Sayı: 5

-

NİTRİK OKSİT SENTAZ 3 (NOS3) GLU298ASP GEN VARYASYONUNUN MEME KANSERLİ HASTALARDA İNCELENMESİ

CANAN CACINA
SOYKAN ARIKAN
YEMLİHA YILDIZ
BAHAR TOPTAŞ
SAİME TURAN
NAZLI ÖZKAN
GURBET KORKMAZ
SEDEN KÜÇÜCÜK
ILHAN YAYLIM
TURGAY İSBİR
Journal
Experimed
Pages
0
Publication Date
2013-10-28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our finding suggest that NOS3 Glu298Asp might be associated with breast cancer risk.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The role of Nitric Oxide (NO) in tumour biology is not well understood.
📊
Key Findings & Data:The aim of present study was to examine Nitric Oxide Synthase 3 (NOS3) Glu298Asp polymorphism in patients with breast cancer.
💡
Conclusion & Impact:Conclusion: Our finding suggest that NOS3 Glu298Asp might be associated with breast cancer risk.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:oksidatif stres · NOS3 geni · varyasyon

Abstract

The role of Nitric Oxide (NO) in tumour biology is not well understood. However, it has been proposed that NO is a highly reactive free radical and plays important roles in growth, progression or metastasis of tumour. Nitric oxide synthases (NOSs) are a family of enzymes that catalyzing the production of (NO) by converting L-arginine to L-citrulline. The aim of present study was to examine Nitric Oxide Synthase 3 (NOS3) Glu298Asp polymorphism in patients with breast cancer. For this purpose, 49 patients with breast cancer and 89 healthy controls were included in the study. The NOS3 Glu298Asp polymorphism were genotyped by PCR-RFLP using peripheral blood samples in our study groups. NOS3 Glu298Asp genotype distribution in the breast cancer patients [GG: 2(4.1%), GT: 22(44.9%), TT: 25(51%)] was statistically different from the healthy control group [GG: 25(28.1%), GT: 34(38.2%), TT: 30(33.7%)] (p=0.024). NOS3 Glu298Asp gene variation T allele frequency was significantly higher in breast cancer patients that of controls (χ2=7.229; p=0.007; OR: 1.228;%95 CI: 1.065-1.415). Conclusion: Our finding suggest that NOS3 Glu298Asp might be associated with breast cancer risk.

Özet

Nitrik Oksit'in (NO) tümör biyolojisindeki rolü tam olarak anlaşılamamış olmasına karşın tümörün büyümesi, gelişmesi ve metastaz gibi durumlarda önemli rol oynayan bir serbest radikal olduğu ileri sürülmektedir. Nitrik oksit sentaz (NOS) enzim ailesi L-sitrulinin, L-arginine dönüşümü sırasında Nitrik oksit (NO), sentezine aracılık eden bir grup katalizörlerdir. Bu çalışmanın amacı Nitrik Oksit Sentaz (NOS3) Glu298Asp polimorfizmini meme kanserli hastalarda araştırmaktır. Bu amaçla 49 meme ve 89 sağlıklı kontrol grubu çalışmaya dahil edilmiştir. Çalışma gruplarımızda NOS3 Glu298Asp polimorfizmi periferal kan örnekleri kullanarak PCR-RFLP yöntemiyle tayin edilmiştir. Meme kanserli hastalarda NOS3 Glu298Asp genotip dağılımı [GG: 2 (4.1%), GT: 22(44.9%), TT: 25(51%)] sağlıklı kontrol grubundan [GG: 25(28.1%), GT: 34(38.2%), TT: 30(33.7%)] istatistiksel olarak anlamlı derecede farklı bulunmuştur (p=0.024). NOS3 Glu298Asp gen varyasyonu T allel frekansı meme kanserli hastalarda kontrol grubuna göre anlamlı şekilde yüksek olarak saptanmıştır (χ2=7.229; p=0.007; OR: 1.228;%95 CI: 1.065-1.415).Çalışmamız sonucunda NOS3 Glu298Asp polimorfizminin meme kanseri riski ile ilişkili olabileceği kanısına varılmıştır.

🔖

Cite This Article

CACINA, C., ARIKAN, S., YILDIZ, Y., TOPTAŞ, B., TURAN, S., ÖZKAN, N., KORKMAZ, G., KÜÇÜCÜK, S., YAYLIM, I., İSBİR, T. (2013). -. Experimed, Cilt: 3 - Sayı: 5, 0. https://ajindex.com/articles/50920

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. American Cancer Society (2006) Cancer Facts and Figures, 2005.
  2. Atlanta, GA,American Cancer Society. MacMahon,B. (2006) Epidemiology and the causes of breast cancer. Int. J. Cancer, 118, 2373–2378.
  3. Lancaster J.R. Jr, Xie K. (2006) Tumors face NO problems? Cancer Res., 66, 6459–6462.
  4. Arnhold J. (2004) Properties, functions, and secretion of human myeloperoxidase. Biochemistry (Mosc), 69, 4–9.
  5. Moncada S, Higgs A. (1993) The L-arginine– nitricoxidepathway.NEnglJMed,329:2002–12.
  6. Lala PK, Orucevic A. (1998) Role of nitric oxide in tumor progression:lessons From experimental tumors.Cancer MetastasisRev, 17:91–106.
  7. Choi BM, Pae HO, Jang SI. et al. (2002) Nitric oxide as a pro-apoptotic as well as anti-apoptotic modulator, J Biochem Mol Biol. 35(1):116-26.
  8. Ghilardi G, Biondi ML, Cecchini F. et al. (2003) Vascular invasion in human breast cancer is correlated to T786C polymorphism of NOS3 gene. Nitric Oxide 9, 118– 1 Marsden PA, Heng HH, Scherer SW, et al. (1993) Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem., 268:17478–17488.
  9. Hao Y., Montiel R., Huang Y. (2010) Endothelial nitric oxide synthase (eNOS) 894 G>T polymorphism is associated with breast cancer risk: a meta-analysis. Breast Cancer Res Treat. Dec;124(3):809-13. doi: 1007/s10549-010-0833-z. Epub 2010 Mar 19. Miller SA, Dykes DD, Polesky HF. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215 McNamara DM, Holubkov R, Postava L. et al. (2003) Effect of the Asp298 Variant of Endothelial Nitric Oxide Synthase on Survival for Patients With Congestive Heart Failure, Circulation, 107;1598-1602.
  10. Kelly RA, Balligand JL, Smith TW. (1996) Nitric oxide and cardiac function. Circ Res., 79:363 380. Drexler H. (1999) Nitric oxide synthases in the failing human heart: a double-edged sword? Circulation., 99:2972–2975.
  11. Heymes C, Vanderheyden M, Bronzwaer JGF. et al. (1999) Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation., 99:3009–3016.
  12. Orucevic A., Bechberger J., Green A.M. et al. (1999) Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumour-cell invasiveness, Int. J. Cancer 81, 889–896.
  13. K. Mortensen, S. Holck, I.J. Christensen, et al. (1999) Endothelial cell nitric oxide synthase in peritumoral microvessels is a favorable prognostic indicator in premenopausal breast cancer patients, Clin. Cancer Res. 5, 1093